{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:05:06Z","timestamp":1784873106448,"version":"3.55.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301924"],"award-info":[{"award-number":["82301924"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-025-08181-6","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:51:34Z","timestamp":1757667094000},"page":"1461-1471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is fondaparinux safe for use during pregnancy? A state-of-the-art review of current evidence"],"prefix":"10.1007","volume":"312","author":[{"given":"Yuexiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurou","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"3","key":"8181_CR1","volume":"3","author":"P Middleton","year":"2021","unstructured":"Middleton P, Shepherd E, Gomersall JC (2021) Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev 3(3):CD001689","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8181_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/187152571302151217124957","volume":"13","author":"RK Chaudhary","year":"2015","unstructured":"Chaudhary RK, Nepal C, Khanal N, Pathak R, Giri S, Bhatt VR (2015) Management and outcome of Heparin-induced thrombocytopenia in pregnancy: a systematic review. Cardiovasc Hematol Agents Med Chem 13(2):92\u201397","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"8181_CR3","unstructured":"Food and Drug Administration (2001). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21-345_Arixtra_Approv.pdf. Accessed 11 Oct 2023"},{"key":"8181_CR4","unstructured":"European Medicines Agency (2010). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/arixtra-epar-summary-public_en.pdf. Accessed 11 Oct 2023"},{"key":"8181_CR5","doi-asserted-by":"publisher","first-page":"107424842211450","DOI":"10.1177\/10742484221145010","volume":"28","author":"RM Bauersachs","year":"2023","unstructured":"Bauersachs RM (2023) Fondaparinux sodium: recent advances in the management of thrombosis. J Cardiovasc Pharmacol Ther 28:10742484221145010","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"8181_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.thromres.2015.04.001","volume":"135","author":"S De Carolis","year":"2015","unstructured":"De Carolis S, di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino D et al (2015) Fondaparinux in pregnancy: could it be a safe option? A review of the literature. Thromb Res 135(6):1049\u20131051","journal-title":"Thromb Res"},{"issue":"4","key":"8181_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.thromres.2011.10.037","volume":"129","author":"M Nagler","year":"2012","unstructured":"Nagler M, Haslauer M, Wuillemin WA (2012) Fondaparinux - data on efficacy and safety in special situations. Thromb Res 129(4):407\u2013417","journal-title":"Thromb Res"},{"key":"8181_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejogrb.2023.05.031","volume":"287","author":"F Mu","year":"2023","unstructured":"Mu F, Wang M, Huang J, Wang F (2023) Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 287:29\u201335","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"8181_CR9","doi-asserted-by":"publisher","first-page":"107602962110145","DOI":"10.1177\/10760296211014575","volume":"27","author":"CE Dempfle","year":"2021","unstructured":"Dempfle CE, Koscielny J, Lindhoff-Last E, Linnemann B, Bux-Gewehr I, Kappert G et al (2021) Fondaparinux Pre-, Peri-, and\/or Postpartum for the Prophylaxis\/Treatment of Venous Thromboembolism (FondaPPP). Clin Appl Thromb Hemost 27:10760296211014576","journal-title":"Clin Appl Thromb Hemost"},{"key":"8181_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.887020","volume":"13","author":"N Muhamad","year":"2022","unstructured":"Muhamad N, Abu MA, Kalok AH, Shafiee MN, Shah SA, Ismail NAM (2022) Safety and effectiveness of fondaparinux as a postpartum thromboprophylaxis during puerperium among Muslim women: a single centre prospective study. Front Pharmacol 13:887020","journal-title":"Front Pharmacol"},{"key":"8181_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.717630","volume":"12","author":"L Zhao","year":"2021","unstructured":"Zhao L, Bi S, Fu J, Qi L, Li L, Fu Y (2021) Retrospective analysis of fondaparinux and low-molecular-weight heparin in the treatment of women with recurrent spontaneous abortion. Front Endocrinol (Lausanne) 12:717630","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8181_CR12","first-page":"5","volume":"26","author":"Z Guo","year":"2020","unstructured":"Guo Z, Liu C, Guo X, Zhang YXL (2020) Comparison between enoxaparin and fondaparinux sodium on anticoagulant therapy in pregnant patient with recurrent miscarriage. Contemporary Med (Chin) 26:5\u20138","journal-title":"Contemporary Med (Chin)"},{"key":"8181_CR13","first-page":"106","volume":"48","author":"H Liu","year":"2021","unstructured":"Liu H, Wang A, Sang X (2021) Effect of enoxaparin and fondaparinux in anticoagulant therapy for re-pregnant women with recurrent miscarriage. Chin J Pract Med (Chin) 48:106\u2013109","journal-title":"Chin J Pract Med (Chin)"},{"issue":"5","key":"8181_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/bjh.13147","volume":"168","author":"E Elsaigh","year":"2015","unstructured":"Elsaigh E, Thachil J, Nash MJ, Tower C, Hay CR, Bullough S et al (2015) The use of fondaparinux in pregnancy. Br J Haematol 168(5):762\u2013764","journal-title":"Br J Haematol"},{"issue":"1","key":"8181_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1527-3466.2002.tb00081.x","volume":"20","author":"KA Bauer","year":"2002","unstructured":"Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA et al (2002) Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 20(1):37\u201352","journal-title":"Cardiovasc Drug Rev"},{"issue":"Suppl 2","key":"8181_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","volume":"41","author":"F Donat","year":"2002","unstructured":"Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1\u20139","journal-title":"Clin Pharmacokinet"},{"issue":"1s","key":"8181_CR17","first-page":"S75","volume":"22","author":"AD Kaye","year":"2019","unstructured":"Kaye AD, Manchikanti L, Novitch MB, Mungrue IN, Anwar M, Jones MR et al (2019) Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 22(1s):S75-s128","journal-title":"Pain Physician"},{"issue":"6","key":"8181_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1517\/14656566.5.6.1373","volume":"5","author":"AG Turpie","year":"2004","unstructured":"Turpie AG (2004) Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5(6):1373\u20131384","journal-title":"Expert Opin Pharmacother"},{"key":"8181_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.pmbts.2019.02.004","volume":"163","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang M, Tan L, Pan N, Zhang L (2019) The clinical use of Fondaparinux: a synthetic heparin pentasaccharide. Prog Mol Biol Transl Sci 163:41\u201353","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"8181_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","volume":"132","author":"American College of O Gynecologists\u2019 Committee on Practice B-O","year":"2018","unstructured":"American College of O Gynecologists\u2019 Committee on Practice B-O (2018) ACOG practice bulletin no 196: thromboembolism in pregnancy. Obstet Gynecol 132(1):e1\u2013e17","journal-title":"Obstet Gynecol"},{"issue":"6","key":"8181_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1701-2163(15)30569-7","volume":"36","author":"WS Chan","year":"2014","unstructured":"Chan WS, Rey E, Kent NE, Group VTEiPGW, Chan WS, Kent NE et al (2014) Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 36(6):527\u2013553","journal-title":"J Obstet Gynaecol Can"},{"key":"8181_CR22","unstructured":"Royal College of Obstetricians and Gynaecologists (2015) Green-top Guideline No. 37a. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. https:\/\/www.rcog.org.uk\/en\/guidelines-research-services\/guidelines\/gtg37a\/. Accessed 10 Oct 2023"},{"key":"8181_CR23","unstructured":"Queensland Clinical Guidelines (2020) Venous thromboembolism (VTE) in pregnancy and the puerperium. Guideline MN20.9-V7-R25. Queensland Health. Available from: http:\/\/www.health.qld.gov.au\/qcg"},{"issue":"2 Suppl","key":"8181_CR24","doi-asserted-by":"publisher","first-page":"e691S","DOI":"10.1378\/chest.11-2300","volume":"141","author":"SM Bates","year":"2012","unstructured":"Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e691S-e736S","journal-title":"Chest"},{"issue":"22","key":"8181_CR25","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","volume":"2","author":"SM Bates","year":"2018","unstructured":"Bates SM, Rajasekhar A, Middeldorp S, McLintock C, Rodger MA, James AH et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2(22):3317\u20133359","journal-title":"Blood Adv"},{"issue":"6","key":"8181_CR26","first-page":"408","volume":"131","author":"Thrombosis Prevention and Treatment Committee of Cardiovascular Physicians Branch CMDA","year":"2018","unstructured":"Thrombosis Prevention and Treatment Committee of Cardiovascular Physicians Branch CMDA (2018) Chinese expert consensus on heparin-induced thrombocytopenia (2017). Chin Med J (Engl) 2017 131(6):408\u2013417","journal-title":"Chin Med J (Engl) 2017"},{"issue":"9","key":"8181_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM200103013440901","volume":"344","author":"AG Turpie","year":"2001","unstructured":"Turpie AG, Gallus AS, Hoek JA, Pentasaccharide I (2001) A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344(9):619\u2013625","journal-title":"N Engl J Med"},{"issue":"6","key":"8181_CR28","first-page":"CD006468","volume":"6","author":"LA Kahale","year":"2018","unstructured":"Kahale LA, Tsolakian IG, Hakoum MB, Matar CF, Barba M, Yosuico VE et al (2018) Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev 6(6):CD006468","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"8181_CR29","volume":"12","author":"GM Brandao","year":"2017","unstructured":"Brandao GM, Junqueira DR, Rollo HA, Sobreira ML (2017) Pentasaccharides for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 12(12):CD011782","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8181_CR30","first-page":"CD004982","volume":"2","author":"M Di Nisio","year":"2018","unstructured":"Di Nisio M, Wichers IM, Middeldorp S (2018) Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2(2):CD004982","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"8181_CR31","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","volume":"363","author":"H Decousus","year":"2010","unstructured":"Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B et al (2010) Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363(13):1222\u20131232","journal-title":"N Engl J Med"},{"issue":"5","key":"8181_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12773","volume":"6","author":"M Tanguay","year":"2022","unstructured":"Tanguay M, S\u00e9guin C (2022) Recurrent thrombosis rescued by fondaparinux in high-risk patients: a case series. Res Pract Thromb Haemost 6(5):e12773","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"8181_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1600-0897.2009.00733.x","volume":"62","author":"EE Winger","year":"2009","unstructured":"Winger EE, Reed JL (2009) A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss. Am J Reprod Immunol 62(4):253\u2013260","journal-title":"Am J Reprod Immunol"},{"issue":"10","key":"8181_CR34","first-page":"55","volume":"60","author":"Y Ni","year":"2022","unstructured":"Ni Y, Ji L, Zhuoying C, Weiwei Li, Jianfen H, Jinhui L et al (2022) Comparison of curative effect of fondaparinux sodium and low molecularweight heparin on recurrent spontaneous abortion. China Mordern Doctor (Chin) 60(10):55\u201358","journal-title":"China Mordern Doctor (Chin)"},{"issue":"8","key":"8181_CR35","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/j.1538-7836.2010.03926.x","volume":"8","author":"HM Knol","year":"2010","unstructured":"Knol HM, Schultinge L, Erwich JJ, Meijer K (2010) Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost 8(8):1876\u20131879","journal-title":"J Thromb Haemost"},{"issue":"4","key":"8181_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/0976-7800.122260","volume":"4","author":"VR Tandon","year":"2013","unstructured":"Tandon VR, Sharma S, Mahajan S, Mahajan A, Khajuria V (2013) A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml. J Mid-life Health 4(4):241\u2013243","journal-title":"J Mid-life Health"},{"issue":"4","key":"8181_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11239-009-0376-5","volume":"29","author":"H Nielly","year":"2010","unstructured":"Nielly H, Bousquet A, Le Garlantezec P, Perrier E, Bohand X (2010) Severe bleeding secondary to misuse of fondaparinux: a case report. J Thromb Thrombolysis 29(4):503\u2013511","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"8181_CR38","doi-asserted-by":"publisher","first-page":"1414.e9","DOI":"10.1016\/j.arth.2011.10.032","volume":"27","author":"MG Hannon","year":"2012","unstructured":"Hannon MG, Lamont JG (2012) Compartment syndrome due to massive leg hematoma after primary total hip arthroplasty: a previously unreported complication of fondaparinux. J Arthroplasty 27(7):1414.e9-.e11","journal-title":"J Arthroplasty"},{"issue":"4","key":"8181_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/bja\/aen255","volume":"101","author":"J Bordes","year":"2008","unstructured":"Bordes J, Asencio Y, Kenane N, Fesselet J, Meaudre E, Goutorbe P (2008) Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux. Br J Anaesth 101(4):575\u2013576","journal-title":"Br J Anaesth"},{"issue":"5","key":"8181_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1076029616675970","volume":"23","author":"P Dhakal","year":"2017","unstructured":"Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR (2017) Reversal of anticoagulation and management of bleeding in patients on anticoagulants. Clin Appl Thromb Hemost 23(5):410\u2013415","journal-title":"Clin Appl Thromb Hemost"},{"issue":"20","key":"8181_CR41","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","volume":"106","author":"NR Bijsterveld","year":"2002","unstructured":"Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ et al (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106(20):2550\u20132554","journal-title":"Circulation"},{"issue":"11","key":"8181_CR42","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1046\/j.1538-7836.2003.00536.x","volume":"1","author":"T Lisman","year":"2003","unstructured":"Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M, Nieuwenhuis HK et al (2003) Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 1(11):2368\u20132373","journal-title":"J Thromb Haemost"},{"issue":"2","key":"8181_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/17482941.2011.567281","volume":"13","author":"P Luporsi","year":"2011","unstructured":"Luporsi P, Chopard R, Janin S, Racadot E, Bernard Y, Ecarnot F et al (2011) Use of recombinant factor VIIa (NovoSeven(\u00ae)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 13(2):93\u201398","journal-title":"Acute Card Care"},{"issue":"3","key":"8181_CR44","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1182\/blood.V91.3.916","volume":"91","author":"JS Suh","year":"1998","unstructured":"Suh JS, Aster RH, Visentin GP (1998) Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91(3):916\u2013922","journal-title":"Blood"},{"issue":"1","key":"8181_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2007-1000374","volume":"21","author":"CL Anderson","year":"1995","unstructured":"Anderson CL, Chacko GW, Osborne JM, Brandt JT (1995) The Fc receptor for immunoglobulin G (Fc gamma RII) on human platelets. Semin Thromb Hemost 21(1):1\u20139","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"8181_CR46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","volume":"25","author":"M Hogan","year":"2020","unstructured":"Hogan M, Berger JS (2020) Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med 25(2):160\u2013173","journal-title":"Vasc Med"},{"issue":"21","key":"8181_CR47","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","volume":"70","author":"M Schindewolf","year":"2017","unstructured":"Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J et al (2017) Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol 70(21):2636\u20132648","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"8181_CR48","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ajh.21032","volume":"82","author":"GK Lo","year":"2007","unstructured":"Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82(12):1037\u20131043","journal-title":"Am J Hematol"},{"issue":"5","key":"8181_CR49","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.12179","volume":"91","author":"VR Bhatt","year":"2013","unstructured":"Bhatt VR, Aryal MR, Shrestha R, Armitage JO (2013) Fondaparinux-associated heparin-induced thrombocytopenia. Eur J Haematol 91(5):437\u2013441","journal-title":"Eur J Haematol"},{"issue":"21","key":"8181_CR50","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2017.09.1098","volume":"70","author":"TE Warkentin","year":"2017","unstructured":"Warkentin TE (2017) Fondaparinux for treatment of heparin-induced thrombocytopenia: too good to be true? J Am Coll Cardiol 70(21):2649\u20132651","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"8181_CR51","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2(22):3360\u20133392","journal-title":"Blood Adv"},{"issue":"37","key":"8181_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012236","volume":"97","author":"Y He","year":"2018","unstructured":"He Y, He H, Liu D, Long Y, Su L, Cheng W (2018) Fondaparinux in a critically ill patient with heparin-induced thrombocytopenia: a case report. Medicine (Baltimore) 97(37):e12236","journal-title":"Medicine (Baltimore)"},{"key":"8181_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijoa.2015.11.009","volume":"26","author":"E Mauermann","year":"2016","unstructured":"Mauermann E, V\u00f6kt C, Tsakiris DA, Tobler D, Girard T (2016) Heparin-induced thrombocytopenia in pregnancy: an interdisciplinary challenge-a case report and literature review. Int J Obstet Anesth 26:79\u201382","journal-title":"Int J Obstet Anesth"},{"issue":"5","key":"8181_CR54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1510\/icvts.2010.247460","volume":"11","author":"J Hajj-Chahine","year":"2010","unstructured":"Hajj-Chahine J, Jayle C, Tomasi J, Corbi P (2010) Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. Interact Cardiovasc Thorac Surg 11(5):679\u2013681","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"5","key":"8181_CR55","doi-asserted-by":"publisher","first-page":"Cs56","DOI":"10.12659\/MSM.881753","volume":"17","author":"M Ciurzy\u0144ski","year":"2011","unstructured":"Ciurzy\u0144ski M, Jankowski K, Pietrzak B, Mazanowska N, Rzewuska E, Kowalik R et al (2011) Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. Med Sci Monit 17(5):Cs56\u2013Cs59","journal-title":"Med Sci Monit"},{"key":"8181_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.thromres.2021.09.001","volume":"207","author":"CA Lovatt","year":"2021","unstructured":"Lovatt CA, Crowther MA (2021) Challenging anticoagulation cases: a case of heparin-induced-thrombocytopenia in the first trimester of pregnancy. Thromb Res 207:58\u201361","journal-title":"Thromb Res"},{"key":"8181_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.thromres.2016.08.020","volume":"146","author":"M Khoury","year":"2016","unstructured":"Khoury M, Pitsis A, Poumpouridou-Kioura H, Soufla G, Kanthou C, Matoula N et al (2016) Acute intraoperative heparin-induced thrombocytopenia (HIT) and thrombosis during coronary artery bypass grafting: two case reports providing evidence for the role of preoperative LMWH in triggering sensitization. Thromb Res 146:126\u2013130","journal-title":"Thromb Res"},{"issue":"5","key":"8181_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1055\/s-2002-35284","volume":"28","author":"E Lindhoff-Last","year":"2002","unstructured":"Lindhoff-Last E, Bauersachs R (2002) Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 28(5):439\u2013446","journal-title":"Semin Thromb Hemost"},{"key":"8181_CR59","unstructured":"Drugs and Lactation Database (LactMed\u00ae). Argatroban. Bethesda (MD): National Institute of Child Health and Human Development; 2006."},{"key":"8181_CR60","unstructured":"Drugs and Lactation Database (LactMed\u00ae) (2006) Lepirudin. Bethesda (MD): National Institute of Child Health and Human Development"},{"issue":"8","key":"8181_CR61","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/acs.bioconjchem.2c00316","volume":"33","author":"LY Chen","year":"2022","unstructured":"Chen LY, Khan N, Lindenbauer A, Nguyen TH (2022) When will Fondaparinux induce thrombocytopenia? Bioconjug Chem 33(8):1574\u20131583","journal-title":"Bioconjug Chem"},{"issue":"5","key":"8181_CR62","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1055\/s-0037-1613092","volume":"87","author":"F Lagrange","year":"2002","unstructured":"Lagrange F, Vergnes C, Brun JL, Paolucci F, Nadal T, Leng JJ et al (2002) Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 87(5):831\u2013835","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"8181_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00003088-200241002-00007","volume":"41","author":"F Lagrange","year":"2002","unstructured":"Lagrange F, Brun JL, Vergnes MC, Paolucci F, Nadal T, Leng JJ et al (2002) Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model. Clin Pharmacokinet 41(Suppl 2):47\u201349","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"8181_CR64","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1056\/NEJM200404293501825","volume":"350","author":"CE Dempfle","year":"2004","unstructured":"Dempfle CE (2004) Minor transplacental passage of fondaparinux in vivo. N Engl J Med 350(18):1914\u20131915","journal-title":"N Engl J Med"},{"issue":"12","key":"8181_CR65","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/jcph.1686","volume":"60","author":"X Yang","year":"2020","unstructured":"Yang X, Li N, Guo T, Guan X, Tan J, Gao X et al (2020) Comparison of the Effects of Low-Molecular-Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism. J Clin Pharmacol 60(12):1671\u20131678","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"8181_CR66","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.3928\/01477447-20130327-17","volume":"36","author":"K Hosaka","year":"2013","unstructured":"Hosaka K, Saito S, Ishii T, Sumino T, Ryu K, Suzuki G et al (2013) Safety of fondaparinux versus enoxaparin after TKA in Japanese patients. Orthopedics 36(4):e428\u2013e433","journal-title":"Orthopedics"},{"issue":"1","key":"8181_CR67","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2012.09.015","volume":"58","author":"L Orostegui","year":"2013","unstructured":"Orostegui L, Medejel N, Kone-Paut I, Dreyfus M, Benhamou D (2013) Fondaparinux (Arixtra *) hepatotoxicity in a 6 year-old child. J Hepatol 58(1):195\u2013198","journal-title":"J Hepatol"},{"issue":"3","key":"8181_CR68","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0039-1685515","volume":"39","author":"A Wree","year":"2019","unstructured":"Wree A, Holtmann TM, Inzaugarat ME, Feldstein AE (2019) Novel drivers of the inflammatory response in liver injury and fibrosis. Semin Liver Dis 39(3):275\u2013282","journal-title":"Semin Liver Dis"},{"issue":"2","key":"8181_CR69","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1124\/jpet.116.237578","volume":"360","author":"RA Roth","year":"2017","unstructured":"Roth RA, Maiuri AR, Ganey PE (2017) Idiosyncratic drug-induced liver injury: is drug-cytokine interaction the linchpin? J Pharmacol Exp Ther 360(2):461\u2013470","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"8181_CR70","doi-asserted-by":"publisher","first-page":"913","DOI":"10.4065\/mcp.2010.0346","volume":"85","author":"M Schindewolf","year":"2010","unstructured":"Schindewolf M, Scheuermann J, Kroll H, Garbaraviciene J, Hecking C, Marzi I et al (2010) Low allergenic potential with fondaparinux: results of a prospective investigation. Mayo Clin Proc 85(10):913\u2013919","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"8181_CR71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.0105-1873.2004.0350j.x","volume":"50","author":"K Hirsch","year":"2004","unstructured":"Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R, Boehncke WH (2004) Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis 50(6):383\u2013384","journal-title":"Contact Dermatitis"},{"issue":"4","key":"8181_CR72","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1160\/TH05-04-0895","volume":"94","author":"J Utikal","year":"2005","unstructured":"Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S et al (2005) Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 94(4):895\u2013896","journal-title":"Thromb Haemost"},{"issue":"2","key":"8181_CR73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/01.mbc.0000214710.19116.40","volume":"17","author":"A Wijesiriwardana","year":"2006","unstructured":"Wijesiriwardana A, Lees DA, Lush C (2006) Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis 17(2):147\u2013149","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"8181_CR74","first-page":"229","volume":"25","author":"A Buonomo","year":"2015","unstructured":"Buonomo A, Nucera E, De Carolis S, De Stefano V, Pascolini L, Di Pasquo E et al (2015) A case of heparin allergy with good tolerability to fondaparinux during pregnancy. J Investig Allergol Clin Immunol 25(3):229\u2013231","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"8181_CR75","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00223-021-00815-6","volume":"110","author":"SA Hardcastle","year":"2022","unstructured":"Hardcastle SA (2022) Pregnancy and lactation associated osteoporosis. Calcif Tissue Int 110(5):531\u2013545","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"8181_CR76","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1191\/0961203302lu262oa","volume":"11","author":"G Ruiz-Irastorza","year":"2002","unstructured":"Ruiz-Irastorza G, Khamashta MA, Hughes GR (2002) Heparin and osteoporosis during pregnancy: 2002 update. Lupus 11(10):680\u2013682","journal-title":"Lupus"},{"issue":"5","key":"8181_CR77","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/MCP.0b013e3283061191","volume":"14","author":"G Le Templier","year":"2008","unstructured":"Le Templier G, Rodger MA (2008) Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 14(5):403\u2013407","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"8181_CR78","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/bjs.4809","volume":"92","author":"AE Handschin","year":"2005","unstructured":"Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92(2):177\u2013183","journal-title":"Br J Surg"},{"issue":"4","key":"8181_CR79","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00223-002-2091-5","volume":"73","author":"G Matziolis","year":"2003","unstructured":"Matziolis G, Perka C, Disch A, Zippel H (2003) Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73(4):370\u2013379","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"8181_CR80","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/jor.21405","volume":"29","author":"A Papathanasopoulos","year":"2011","unstructured":"Papathanasopoulos A, Kouroupis D, Henshaw K, McGonagle D, Jones EA, Giannoudis PV (2011) Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells. J Orthop Res 29(9):1327\u20131335","journal-title":"J Orthop Res"},{"issue":"7","key":"8181_CR81","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/0091270011409231","volume":"52","author":"S Harder","year":"2012","unstructured":"Harder S (2012) Renal profiles of anticoagulants. J Clin Pharmacol 52(7):964\u2013975","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"8181_CR82","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s11239-012-0773-z","volume":"34","author":"Y Yukizawa","year":"2012","unstructured":"Yukizawa Y, Inaba Y, Watanabe S, Yajima S, Kobayashi N, Ishida T et al (2012) Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty. J Thromb Thrombolysis 34(4):526\u2013532","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"8181_CR83","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/bcp.13663","volume":"84","author":"PJ Zufferey","year":"2018","unstructured":"Zufferey PJ, Ollier E, Delavenne X, Laporte S, Mismetti P, Duffull SB (2018) Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis. Br J Clin Pharmacol 84(10):2242\u20132251","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"8181_CR84","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/phar.2014","volume":"37","author":"KA Wahby","year":"2017","unstructured":"Wahby KA, Riley LK, Tennenberg SD (2017) Assessment of an extended interval fondaparinux dosing regimen for venous thromboembolism prophylaxis in critically ill patients with severe renal dysfunction using antifactor Xa levels. Pharmacotherapy 37(10):1241\u20131248","journal-title":"Pharmacotherapy"},{"issue":"6","key":"8181_CR85","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1160\/TH11-09-0640","volume":"107","author":"P Mismetti","year":"2012","unstructured":"Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B et al (2012) Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. Thromb Haemost 107(6):1151\u20131160","journal-title":"Thromb Haemost"},{"issue":"11","key":"8181_CR86","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1111\/j.1538-7836.2012.04908.x","volume":"10","author":"W Ageno","year":"2012","unstructured":"Ageno W, Riva N, Noris P, Di Nisio M, La Regina M, Arioli D et al (2012) Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost 10(11):2291\u20132297","journal-title":"J Thromb Haemost"},{"issue":"1","key":"8181_CR87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J (2016) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41(1):206\u2013232","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"8181_CR88","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/s-0040-1718405","volume":"46","author":"A Abildgaard","year":"2020","unstructured":"Abildgaard A, Madsen SA, Hvas AM (2020) Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 46(8):932\u2013969","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"8181_CR89","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/1060028020930186","volume":"54","author":"W Wongcharoen","year":"2020","unstructured":"Wongcharoen W, Tantisirivit N, Norasetthada L, Gunaparn S, Phrommintikul A (2020) Anti-factor Xa activity of fixed-dose fondaparinux in low-body-weight patients with acute coronary syndrome. Ann Pharmacother 54(11):1083\u20131089","journal-title":"Ann Pharmacother"},{"issue":"6","key":"8181_CR90","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5414\/CP203169","volume":"56","author":"K Hanada","year":"2018","unstructured":"Hanada K, Shibata S, Takashima Y, Matsuo T, Iwa K, Matsubara H et al (2018) Population pharmacokinetics and pharmacodynamics of fondaparinux in Japanese patients after artificial total knee replacement. Int J Clin Pharmacol Ther 56(6):255\u2013262","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"8181_CR91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00228-021-03201-1","volume":"78","author":"D Michali\u010dkov\u00e1","year":"2022","unstructured":"Michali\u010dkov\u00e1 D, Hartinger JM, Hladinov\u00e1 Z, Bedn\u00e1\u0159ov\u00e1 V, Szonowsk\u00e1 B, Polakovi\u010d V et al (2022) Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol 78(1):89\u201398","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"8181_CR92","doi-asserted-by":"publisher","first-page":"18083","DOI":"10.1038\/s41598-025-03365-1","volume":"15","author":"A Aszkie\u0142owicz","year":"2025","unstructured":"Aszkie\u0142owicz A, Steckiewicz KP, Owczuk R (2025) Evaluating the impact of continuous venovenous hemodiafiltration on the efficacy of prophylactic fondaparinux doses: a prospective single-center observational study. Sci Rep 15(1):18083","journal-title":"Sci Rep"},{"issue":"2","key":"8181_CR93","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/labmed\/lmy054","volume":"50","author":"EM Staley","year":"2019","unstructured":"Staley EM, Simmons SC, Feldman AZ, Williams LA, Pham HP (2019) Monitoring fondaparinux in the setting of antithrombin deficiency. Lab Med 50(2):208\u2013211","journal-title":"Lab Med"},{"issue":"1","key":"8181_CR94","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.5858\/arpa.2023-0496-OA","volume":"149","author":"L Ling","year":"2025","unstructured":"Ling L, Liu C, Huang X, Liu S, Liao J, Jia J et al (2025) Anti-Xa activity test is needed but is not enough for monitoring fondaparinux therapy among critically ill patients. Arch Pathol Lab Med 149(1):e11\u2013e18","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"8181_CR95","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajh.22222","volume":"87","author":"E Gehrie","year":"2012","unstructured":"Gehrie E, Laposata M (2012) Test of the month: the chromogenic antifactor Xa assay. Am J Hematol 87(2):194\u2013196","journal-title":"Am J Hematol"},{"issue":"3","key":"8181_CR96","first-page":"261","volume":"43","author":"JL Babin","year":"2017","unstructured":"Babin JL, Traylor KL, Witt DM (2017) Laboratory monitoring of low-molecular-weight heparin and fondaparinux. Semin Thromb Hemost 43(3):261\u2013269","journal-title":"Semin Thromb Hemost"},{"key":"8181_CR97","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/126975","volume":"2015","author":"S Yentz","year":"2015","unstructured":"Yentz S, Onwuemene OA, Stein BL, Cull EH, McMahon B (2015) Clinical use of anti-xa monitoring in malignancy-associated thrombosis. Thrombosis 2015:126975","journal-title":"Thrombosis"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-025-08181-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:03:00Z","timestamp":1762329780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-025-08181-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":97,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["8181"],"URL":"https:\/\/doi.org\/10.1007\/s00404-025-08181-6","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}